{"filing":{"accession_number":"0001104659-26-072425","cik":"0001211583","ticker":"FENC","company_name":"FENNEC PHARMACEUTICALS INC.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"tm2617550d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926072425/tm2617550d1_8k.htm"},"events":[{"id":5616,"run_id":4924,"accession_number":"0001104659-26-072425","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on six proposals: election of five directors (Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, Jeffrey Hackman), appointment of auditors (Haskell \u0026 White LLP), advisory votes on executive compensation and frequency thereof, amendments to the 2020 Equity Incentive Plan, and adoption of the 2026 Equity Inducement Plan. All proposals were approved by shareholders on June 10, 2026. This is material as it confirms governance and compensation decisions affecting the company's leadership and capital structure.","company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5991,"accession_number":"0001104659-26-072425","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on six proposals: election of five directors (Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, Jeffrey Hackman), appointment of auditors (Haskell \u0026 White LLP), advisory votes on executive compensation and frequency thereof, amendments to the 2020 Equity Incentive Plan, and adoption of the 2026 Equity Inducement Plan. All proposals were approved by shareholders on June 10, 2026. This is material as it confirms governance and compensation decisions affecting the company's leadership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:20:06.514567+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5991,"accession_number":"0001104659-26-072425","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on six proposals: election of five directors (Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, Jeffrey Hackman), appointment of auditors (Haskell \u0026 White LLP), advisory votes on executive compensation and frequency thereof, amendments to the 2020 Equity Incentive Plan, and adoption of the 2026 Equity Inducement Plan. All proposals were approved by shareholders on June 10, 2026. This is material as it confirms governance and compensation decisions affecting the company's leadership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:20:06.514567+00:00","company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","filing_date":"2026-06-10"}]}